Hemogenyx Pharmaceuticals PLC Announces Invitation to Participate at DCNY Summit

Rhea-AI Summary

Hemogenyx Pharmaceuticals (OTCQB:HOPHF) has been invited to present at the prestigious DCNY Summit, taking place in Washington, DC on September 18, 2025, and in New York on September 22, 2025. The summit, co-hosted by the Alliance Indus Foundation and various international partners, brings together policymakers, investors, and corporate leaders.

During the event, Hemogenyx will showcase its clinical progress, including updates on its Phase I clinical trial of CAR-T cell therapy for acute myeloid leukemia (AML). The company will have the opportunity to engage with key stakeholders and potential investors, as the summit has previously helped participants secure significant growth capital.

Hemogenyx Pharmaceuticals Invited to Participate at DCNY Summit

LONDON, UK / ACCESS Newswire / September 11, 2025 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), is pleased to announce that the Company has been invited to participate and present at the upcoming DCNY Summit, taking place in Washington, DC on 18 September 2025 and in New York on 22 September 2025.

The DCNY Summit is co-hosted by the Alliance Indus Foundation, together with Congressional leaders, the Embassy of India, Saudi Vision Invest, and other international partners, and is designed as a high-level forum connecting Washington, DC and New York to bring together policymakers, investors, corporate leaders, and innovators.

Hemogenyx will present its clinical progress and pipeline as part of the Summit's curated company showcase. Previous Summit participants have successfully secured significant growth capital, underscoring the Summit's reputation as a catalyst for financing and partnerships.

Participation in the DCNY Summit provides Hemogenyx with a valuable platform to:

• Highlight recent clinical milestones, including the ongoing Phase I clinical trial of its lead CAR-T cell therapy for acute myeloid leukemia (AML);

• Showcase the Company's broader therapeutic pipeline to an audience of influential stakeholders;

• Engage directly with investors, collaborators, and decision-makers at the intersection of science, healthcare, and finance.

Dr. Vladislav Sandler, CEO & Co-Founder of Hemogenyx Pharmaceuticals, commented:

"We are honored to have been invited to present Hemogenyx at the DCNY Summit. This prestigious event convenes a remarkable group of global investors, corporate leaders, and policymakers, and provides us with a unique opportunity to highlight our progress and to engage with those who can help accelerate our mission to transform the treatment of cancer."

Enquiries:

Hemogenyx Pharmaceuticals plc	https://hemogenyx.com
Dr Vladislav Sandler, Chief Executive Officer & Co-Founder	headquarters@hemogenyx.com
Peter Redmond, Director	peter.redmond@hemogenyx.com
SP Angel Corporate Finance LLP	Tel: +44 (0)20 3470 0470
Matthew Johnson, Vadim Alexandre, Adam Cowl
Peterhouse Capital Limited	Tel: +44 (0)20 7469 0930
Lucy Williams, Duncan Vasey, Charles Goodfellow

About DCNY Summit

The DCNY Summit (https://dcnysummit.org) is an annual high-level forum connecting Washington, DC and New York to bring together policymakers, corporate leaders, investors, and innovators. It is co-hosted by the Alliance Indus Foundation in partnership with Congressional leaders, the Embassy of India, Saudi Vision Invest, and other global organizations. The Summit serves as a platform for showcasing transformative companies, fostering international collaboration, and catalyzing financing and innovation across life sciences, healthcare, and technology sectors.

About Hemogenyx Pharmaceuticals plc

Hemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, located in New York City.

The Company is a clinical stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune diseases. Hemogenyx Pharmaceuticals is developing several distinct and complementary product candidates, as well as platform technologies that it uses as engines for novel product development.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

SOURCE: Hemogenyx Pharmaceuticals PLC

View the original press release on ACCESS Newswire

FAQ

When and where will Hemogenyx Pharmaceuticals (HOPHF) present at the DCNY Summit 2025?

Hemogenyx will present at the DCNY Summit in Washington, DC on September 18, 2025, and in New York on September 22, 2025.

What will Hemogenyx Pharmaceuticals showcase at the DCNY Summit 2025?

Hemogenyx will present its clinical progress and pipeline, including updates on its Phase I clinical trial of CAR-T cell therapy for acute myeloid leukemia (AML).

Who are the co-hosts of the DCNY Summit 2025?

The summit is co-hosted by the Alliance Indus Foundation, along with Congressional leaders, the Embassy of India, Saudi Vision Invest, and other international partners.

What is the significance of Hemogenyx's participation in the DCNY Summit?

The summit provides Hemogenyx a platform to showcase its therapeutic pipeline, engage with investors and stakeholders, and potentially secure growth capital, as previous participants have successfully done.